Patents by Inventor Linda H. Malkas

Linda H. Malkas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PCNA INHIBITORS
    Publication number: 20220340516
    Abstract: Described herein, inter alia, are compositions of PCNA modulators and methods for treating or preventing cancer.
    Type: Application
    Filed: April 27, 2022
    Publication date: October 27, 2022
    Inventors: Linda H. Malkas, David Horne, Robert J. Hickey, Long Gu
  • PCNA inhibitors
    Patent number: 11345656
    Abstract: Described herein, inter alia, are compositions of PCNA modulators and methods for treating or preventing cancer.
    Type: Grant
    Filed: December 1, 2020
    Date of Patent: May 31, 2022
    Assignee: City of Hope
    Inventors: Linda H. Malkas, David Horne, Robert J. Hickey, Long Gu
  • csPCNA Isoform Antibodies And Uses Thereof
    Publication number: 20220048980
    Abstract: Antibodies specifically bind only to a cancer specific proliferating cell nuclear antigen (csPCNA) isoform and not to the non-malignant proliferating cell nuclear antigen (nmPCNA) isoform. Methods and compositions to detect the presence of csPCNA isoform are disclosed.
    Type: Application
    Filed: March 23, 2021
    Publication date: February 17, 2022
    Inventors: Robert J. HICKEY, Linda H. MALKAS, Lauren SCHNAPER
  • PCNA INHIBITORS
    Publication number: 20210078938
    Abstract: Described herein, inter alia, are compositions of PCNA modulators and methods for treating or preventing cancer.
    Type: Application
    Filed: December 1, 2020
    Publication date: March 18, 2021
    Inventors: Linda H. Malkas, David Horne, Robert J. Hickey, Long Gu
  • PCNA inhibitors
    Patent number: 10913706
    Abstract: Described herein, inter alia, are compositions of PCNA modulators and methods for treating or preventing cancer.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: February 9, 2021
    Assignee: CITY OF HOPE
    Inventors: Linda H. Malkas, David Horne, Robert J. Hickey, Long Gu
  • PCNA INHIBITORS
    Publication number: 20200216386
    Abstract: Described herein, inter alia, are compositions of PCNA modulators and methods for treating or preventing cancer.
    Type: Application
    Filed: December 13, 2019
    Publication date: July 9, 2020
    Inventors: Linda H. Malkas, David Horne, Robert J. Hickey, Long Gu
  • PCNA inhibitors
    Patent number: 10550070
    Abstract: Described herein, inter alia, are compositions of PCNA modulators and methods for treating or preventing cancer.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: February 4, 2020
    Assignee: CITY OF HOPE
    Inventors: Linda H. Malkas, David Horne, Robert J. Hickey, Long Gu
  • CAPCNA PEPTIDE THERAPEUTICS FOR CANCER
    Publication number: 20190388504
    Abstract: Administration of compositions comprising cell-permeable cancer-specific proliferating cell nuclear antigen derived peptides and their variants reduces the proliferation of cancer cells and also augments cytotoxic effects of chemotherapeutics. The compositions are effective in cells harboring mutations in DNA repair proteins.
    Type: Application
    Filed: January 29, 2019
    Publication date: December 26, 2019
    Inventors: Robert J. Hickey, Linda H. Malkas
  • Anticancer therapeutic agents
    Patent number: 10420840
    Abstract: The invention described herein pertains to anticancer therapeutic agents that exhibit preferential cytotoxicity to malignant cells that express a cancer specific isoform of proliferating cell nuclear antigen (caPCNA) compared to cytotoxicity to comparable non-malignant cells, pharmaceutical compositions comprising the agents, and their use in cancer therapy.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: September 24, 2019
    Assignee: RLL, LLC
    Inventors: Robert J. Hickey, Linda H. Malkas
  • CAPCNA peptide therapeutics for cancer
    Patent number: 10188699
    Abstract: Administration of compositions comprising cell-permeable cancer-specific proliferating cell nuclear antigen derived peptides and their variants reduces the proliferation of cancer cells and also augments cytotoxic effects of chemotherapeutics. The compositions are effective in cells harboring mutations in DNA repair proteins.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: January 29, 2019
    Inventors: Robert J. Hickey, Linda H. Malkas
  • csPCNA Isoform Antibodies And Uses Thereof
    Publication number: 20180362626
    Abstract: Antibodies specifically bind only to a cancer specific proliferating cell nuclear antigen (csPCNA) isoform and not to the non-malignant proliferating cell nuclear antigen (nmPCNA) isoform. Methods and compositions to detect the presence of csPCNA isoform are disclosed.
    Type: Application
    Filed: March 5, 2018
    Publication date: December 20, 2018
    Inventors: Robert J. HICKEY, Linda H. MALKAS, Lauren SCHNAPER
  • PCNA INHIBITORS
    Publication number: 20180339960
    Abstract: Described herein, inter alia, are compositions of PCNA modulators and methods for treating or preventing cancer.
    Type: Application
    Filed: September 16, 2016
    Publication date: November 29, 2018
    Inventors: Linda H. Malkas, David Horne, Robert J. Hickey, Long Gu
  • CAPCNA PEPTIDE THERAPEUTICS FOR CANCER
    Publication number: 20170157210
    Abstract: Administration of compositions comprising cell-permeable cancer-specific proliferating cell nuclear antigen derived peptides and their variants reduces the proliferation of cancer cells and also augments cytotoxic effects of chemotherapeutics. The compositions are effective in cells harboring mutations in DNA repair proteins.
    Type: Application
    Filed: November 17, 2016
    Publication date: June 8, 2017
    Inventors: Robert J. HICKEY, Linda H. MALKAS
  • CAPCNA peptide therapeutics for cancer
    Patent number: 9527895
    Abstract: Administration of compositions comprising cell-permeable cancer-specific proliferating cell nuclear antigen derived peptides and their variants reduces the proliferation of cancer cells and also augments cytotoxic effects of chemotherapeutics. The compositions are effective in cells harboring mutations in DNA repair proteins.
    Type: Grant
    Filed: October 3, 2013
    Date of Patent: December 27, 2016
    Inventors: Robert J. Hickey, Linda H. Malkas
  • PEPTIDE BASED INHIBITION OF caPCNA INTERACTION IN CANCER
    Publication number: 20160304559
    Abstract: Peptides derived from cancer specific isoform of proliferating cell nuclear antigen (caPCNA, also known as csPCNA) or from nmPCNA-interacting proteins interfere with intracellular protein-protein interaction, thereby causing a reduction in the proliferative potential of cancer. These peptides serve as therapeutic compositions to reduce the proliferation of cancer cells and also augment existing chemotherapeutic methods.
    Type: Application
    Filed: October 29, 2015
    Publication date: October 20, 2016
    Inventors: Robert J. HICKEY, Linda H. MALKAS
  • ANTICANCER THERAPEUTIC AGENTS
    Publication number: 20160296482
    Abstract: The invention described herein pertains to anticancer therapeutic agents that exhibit preferential cytotoxicity to malignant cells that express a cancer specific isoform of proliferating cell nuclear antigen (caPCNA) compared to cytotoxicity to comparable non-malignant cells, pharmaceutical compositions comprising the agents, and their use in cancer therapy.
    Type: Application
    Filed: April 10, 2015
    Publication date: October 13, 2016
    Inventors: Robert J. HICKEY, Linda H. MALKAS
  • Peptide based inhibition of caPCNA interaction in cancer
    Patent number: 9187526
    Abstract: Peptides derived from cancer specific isoform of proliferating cell nuclear antigen (caPCNA, also known as csPCNA) or from nmPCNA-interacting proteins interfere with intracellular protein-protein interaction, thereby causing a reduction in the proliferative potential of cancer. These peptides serve as therapeutic compositions to reduce the proliferation of cancer cells and also augment existing chemotherapeutic methods.
    Type: Grant
    Filed: February 18, 2014
    Date of Patent: November 17, 2015
    Inventors: Robert J. Hickey, Linda H. Malkas
  • csPCNA Isoform Antibodies And Uses Thereof
    Publication number: 20150259407
    Abstract: Antibodies specifically bind only to a cancer specific proliferating cell nuclear antigen (csPCNA) isoform and not to the non-malignant proliferating cell nuclear antigen (nmPCNA) isoform. Methods and compositions to detect the presence of csPCNA isoform are disclosed.
    Type: Application
    Filed: March 12, 2015
    Publication date: September 17, 2015
    Inventor: Linda H. MALKAS
  • CsPCNA isoform antibodies and uses thereof
    Patent number: 9006396
    Abstract: Antibodies specifically bind only to a cancer specific proliferating cell nuclear antigen (csPCNA) isoform and not to the non-malignant proliferating cell nuclear antigen (nmPCNA) isoform. Methods and compositions to detect the presence of csPCNA isoform are disclosed.
    Type: Grant
    Filed: May 22, 2012
    Date of Patent: April 14, 2015
    Inventors: Robert J. Hickey, Linda H. Malkas, Lauren Schnaper
  • PEPTIDE BASED INHIBITION OF caPCNA INTERACTION IN CANCER
    Publication number: 20140296156
    Abstract: Peptides derived from cancer specific isoform of proliferating cell nuclear antigen (caPCNA, also known as csPCNA) or from nmPCNA-interacting proteins interfere with intracellular protein-protein interaction, thereby causing a reduction in the proliferative potential of cancer. These peptides serve as therapeutic compositions to reduce the proliferation of cancer cells and also augment existing chemotherapeutic methods.
    Type: Application
    Filed: February 18, 2014
    Publication date: October 2, 2014
    Inventors: Linda H. Malkas, Robert J. Hickey